The Effectiveness of the Original Drug Trimetazidine MV in Patients with Stable Ischemic Heart Disease and Persistent Angina Attacks Against the Background of the Use of Trimetazidine Generics

Abstract

Goal. To determine the clinical benefits of therapy with the original trimetazidine drug (Preductal® MV) in patients with stable angina pectoris and persistent attacks of anginal pain treated with trimetazidine generics.

Material and methods. The study included 84 patients with stable angina and persistent angina attacks receiving generic trimetazidine against the background of basic therapy of coronary heart disease (CHD). All patients were prescribed Preductal® instead of trimetazidine generics MV 35 mg 2 times a day. The duration of follow—up was 3 months. The effectiveness of treatment was assessed by changes in the frequency of angina attacks, the need for short-acting nitrates and the dynamics of the general condition on a visual analog scale (VAS). Pharmacoeconomical analysis of the effectiveness of therapy was performed.

Results. Replacement of trimetazidine generics with Preductal® MV was accompanied by a decrease in the number of anginal pain attacks by 63%, the number of tablets/doses of nitroglycerin consumed by 65% (p<0.01). During therapy, the number of VAS scores increased from 45.3±13.8 to 71.6±11.9 (p<0.0001). Treatment with Preduktal® MV is the most rational from the standpoint of pharmacoeconomics, since the ratio “the cost of therapy for 1 week. in rubles/number of prevented angina attacks per week.” minimally when using the original drug.

Conclusion. In patients with coronary artery disease with stable angina pectoris and persistent attacks of anginal pain against the background of the use of trimetazidine generics, transfer to Preduktal® MV provides a significant reduction in the frequency of angina attacks and the need for short-acting nitrates. Preduktal® MV is more cost-effective and provides optimal efficiency at minimal cost.